| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-05 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.24 | 6e-05 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.19 | 0.0009 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.1 | 0.006 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.15 | 0.009 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.36 | 0.01 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.01 |